Peer-influenced content. Sources you trust. No registration required. This is HCN.

Clinical Oncology NewsAcetaminophen May Worsen Response to Immunotherapy in Cancer Patients

When immune checkpoint inhibitor therapy was started, detectable levels of acetaminophen in the plasma were linked to significantly poorer PFS and OS. The fact that poorer clinical outcomes were demonstrated to be unrelated to other prognostic variables, such as age, performance status, the quantity of past lines of therapy, and tumor kind, is noteworthy.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form